Although these data confirm previous studies showing that SERMs could decrease IGF-1 and increased IGFBP-3 plasma levels, hence reducing the IGF-1/IGFBP-3 ratio [84–86], they could not clarify the link between BD changes and IGF-1 pathway. This evidence concerns the gene IGF1 and Behcet disease.